NYSE:NGMNGM Biopharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding NGM Biopharmaceuticals Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $20.37 +0.79 (+4.03 %) (As of 06/3/2020 04:00 PM ET) Add Compare Share Today's Range$19.11Now: $20.37▼$20.4750-Day Range$14.92MA: $18.87▼$22.2152-Week Range$8.81Now: $20.37▼$23.39Volume196,200 shsAverage Volume334,662 shsMarket Capitalization$1.39 billionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include Aldafermin, an engineered variant of the FGF19 human hormone in Phase 2b clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b clinical trial for use in the treatment of type 2 diabetes and NASH; and NGM395, which is engineered variant of the GDF15 human hormone for use in the treatment of metabolic syndrome. Its products under development also comprise NGM120, an inhibitory antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in Phase 1 clinical trials to decrease levels of a protein implicated in the dry form of AMD. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 4.6 Analyst's Opinion Consensus RatingNGM Biopharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.40, NGM Biopharmaceuticals has a potential upside of 49.0% from its current price of $20.40.Amount of Analyst CoverageNGM Biopharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.3 Community Rank Outperform VotesNGM Biopharmaceuticals has received 51 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNGM Biopharmaceuticals has received 26 “underperform” votes. (Add your “underperform” vote.)Community SentimentNGM Biopharmaceuticals has received 66.23% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about NGM Biopharmaceuticals and other stocks. Vote “Outperform” if you believe NGM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NGM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNGM Biopharmaceuticals does not currently pay a dividend.Dividend GrowthNGM Biopharmaceuticals does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NGM Biopharmaceuticals insiders have bought 55,395.29% more of their company's stock than they have sold. Specifically, they have bought $19,070,403.00 in company stock and sold $34,364.00 in company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 4.6Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.18 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSE:NGM Previous Symbol CUSIPN/A CIKN/A Webwww.ngmbio.com Phone650-243-5555Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees186 Outstanding Shares68,142,000Market Cap$1.39 billion Next Earnings Date8/10/2020 (Estimated) OptionableNot Optionable NGM Rates by TradingView Receive NGM News and Ratings via Email Sign-up to receive the latest news and ratings for NGM and its competitors with MarketBeat's FREE daily newsletter. NGM Biopharmaceuticals (NYSE:NGM) Frequently Asked Questions How has NGM Biopharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? NGM Biopharmaceuticals' stock was trading at $15.35 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NGM stock has increased by 32.9% and is now trading at $20.40. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of NGM Biopharmaceuticals? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NGM Biopharmaceuticals in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for NGM Biopharmaceuticals. When is NGM Biopharmaceuticals' next earnings date? NGM Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for NGM Biopharmaceuticals. How were NGM Biopharmaceuticals' earnings last quarter? NGM Biopharmaceuticals (NYSE:NGM) announced its quarterly earnings data on Wednesday, May, 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.27) by $0.01. The business had revenue of $24.36 million for the quarter, compared to the consensus estimate of $19.92 million. View NGM Biopharmaceuticals' earnings history. What price target have analysts set for NGM? 5 brokers have issued 12 month price targets for NGM Biopharmaceuticals' stock. Their forecasts range from $28.00 to $32.00. On average, they expect NGM Biopharmaceuticals' share price to reach $30.40 in the next year. This suggests a possible upside of 49.0% from the stock's current price. View analysts' price targets for NGM Biopharmaceuticals. What are Wall Street analysts saying about NGM Biopharmaceuticals stock? Here are some recent quotes from research analysts about NGM Biopharmaceuticals stock: 1. According to Zacks Investment Research, "NGM Biopharmaceuticals Inc. is focused on developing novel therapeutics for underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's product pipeline consists of NGM282, NGM313, NGM120, NGM217, NGM621, NGM386 and NGM395 which are in clinical stage. NGM Biopharmaceuticals Inc. is based in San Francisco, California. " (5/19/2020) 2. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating and $26 target price after NGM reported its 2Q19 financials and business update. We remain positively biased ahead of NGM282’s (aldafermin) Phase 2 cohort 4 interim data expected in 4Q19 (non-invasive biomarkers), but more importantly, aldafermin’s top line results in early 2020 where we believe it has the potential to demonstrate a histological fibrosis benefit in NASH patients in as little as 24 weeks of treatment. The latter remains the key catalyst for the stock, in our view. In the press release, NGM indicated it had completed enrollment for cohort 4 and management also highlighted pipeline progress for some of its earlier stage programs including for NGM621, which is being developed for geographic atrophy, and NGM120 for CACS." (8/14/2019) Has NGM Biopharmaceuticals been receiving favorable news coverage? News coverage about NGM stock has been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. NGM Biopharmaceuticals earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutNGM Biopharmaceuticals. Who are some of NGM Biopharmaceuticals' key competitors? Some companies that are related to NGM Biopharmaceuticals include MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (MOR), MorphoSys (MOR), Vir Biotechnology (VIR), MorphoSys (MOR), BTG (BTG), Abcam (ABC), Cronos Group (CRON), Kodiak Sciences (KOD), Viela Bio (VIE), Genus (GNS), Mesoblast (MSB), Polynovo (PNV), Concordia International (CXR), Clinuvel Pharmaceuticals (CUV) and Trillium Therapeutics (TRIL). View all competitors. What other stocks do shareholders of NGM Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other NGM Biopharmaceuticals investors own include Alibaba Group (BABA), AT&T (T), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Opko Health (OPK), Johnson & Johnson (JNJ), Amarin (AMRN), Pfizer (PFE), Delta Air Lines (DAL) and Gilead Sciences (GILD). Who are NGM Biopharmaceuticals' key executives? NGM Biopharmaceuticals' management team includes the following people: Mr. William J. Rieflin J.D., Exec. Chairman of Directors (Age 60)Dr. David J. Woodhouse, CEO, Acting CFO & Director (Age 49, Pay $615.75k)Dr. Jin-Long Chen, Founder, Chief Scientific Officer & Director (Age 57, Pay $625.75k)Dr. Aetna Wun Trombley, Consultant (Age 40, Pay $550.75k)Ms. Valerie L. Pierce, Sr. VP, Gen. Counsel & Chief Compliance Officer (Age 57) When did NGM Biopharmaceuticals IPO? (NGM) raised $100 million in an initial public offering (IPO) on Thursday, April 4th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Cowen acted as the underwriters for the IPO. What is NGM Biopharmaceuticals' stock symbol? NGM Biopharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "NGM." Who are NGM Biopharmaceuticals' major shareholders? NGM Biopharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (3.32%), State Street Corp (0.68%), Jasper Ridge Partners L.P. (0.46%), JPMorgan Chase & Co. (0.36%), Geode Capital Management LLC (0.35%) and Nuveen Asset Management LLC (0.17%). Company insiders that own NGM Biopharmaceuticals stock include David V Goeddel, Group L P Column, Hsiao D Lieu, Jin-Long Chen, Merck & Co, Inc, Peter Svennilson and Suzanne Sawochka Hooper. View institutional ownership trends for NGM Biopharmaceuticals. Which institutional investors are selling NGM Biopharmaceuticals stock? NGM stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, BlackRock Inc., Morgan Stanley, JPMorgan Chase & Co., UBS Group AG, Victory Capital Management Inc., Victory Capital Management Inc., and Legal & General Group Plc. Company insiders that have sold NGM Biopharmaceuticals company stock in the last year include Group L P Column, Hsiao D Lieu, and Jin-Long Chen. View insider buying and selling activity for NGM Biopharmaceuticals. Which institutional investors are buying NGM Biopharmaceuticals stock? NGM stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Geode Capital Management LLC, Engineers Gate Manager LP, Russell Investments Group Ltd., Bank of New York Mellon Corp, Parametric Portfolio Associates LLC, Alliancebernstein L.P., and Wells Fargo & Company MN. Company insiders that have bought NGM Biopharmaceuticals stock in the last two years include David V Goeddel, Group L P Column, Merck & Co, Inc, Peter Svennilson, and Suzanne Sawochka Hooper. View insider buying and selling activity for NGM Biopharmaceuticals. How do I buy shares of NGM Biopharmaceuticals? Shares of NGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is NGM Biopharmaceuticals' stock price today? One share of NGM stock can currently be purchased for approximately $20.40. How big of a company is NGM Biopharmaceuticals? NGM Biopharmaceuticals has a market capitalization of $1.39 billion. NGM Biopharmaceuticals employs 186 workers across the globe. What is NGM Biopharmaceuticals' official website? The official website for NGM Biopharmaceuticals is www.ngmbio.com. How can I contact NGM Biopharmaceuticals? The company can be reached via phone at 650-243-5555. This page was last updated on 6/3/2020 by MarketBeat.com Staff
